New and investigational triazole agents for the treatment of invasive fungal infections. - Wikidata - wikimedia - TriplyDB

New and investigational triazole agents for the treatment of invasive fungal infections.

New and investigational triazole agents for the treatment of invasive fungal infections.

http://www.wikidata.org/entity/Q37364295

about

Clinical hepatotoxicity associated with antifungal agents.Mycetoma medical therapy.Pharmacological properties of antifungal drugs with a focus on anidulafungin.Invasive candidiasis: update on current pharmacotherapy options and future perspectives.Azole antifungals: 35 years of invasive fungal infection management.In vitro studies of the activity of dithiocarbamate organoruthenium complexes against clinically relevant fungal pathogens.Does topical voriconazole trigger dysplastic changes on the ocular surface?

P2860

Q34546811-34B1521D-84AD-455E-B7A8-2531CEBAD7A1 Q35351362-78CBA83B-9C31-42BD-B1A9-7A1EDA7E99A1 Q37624716-CAE6B545-F826-4418-B2C2-7EA9B5DF034E Q38110850-6A119E8E-63F1-4F14-BA48-FDCCABDC1518 Q38406393-690DB362-67AE-409D-AE86-D311C2885283 Q38989873-4F799EC9-283B-4B96-ACE4-7EB7DBFC9ED2 Q43480251-2B583DB6-0631-4A3A-8061-91FA62CDA934

P2860

New and investigational triazole agents for the treatment of invasive fungal infections.

http://www.wikidata.org/entity/Q37364295

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

New and investigational triazole agents for the treatment of invasive fungal infections.

@en

New and investigational triazole agents for the treatment of invasive fungal infections.

@nl

type

label

New and investigational triazole agents for the treatment of invasive fungal infections.

@en

New and investigational triazole agents for the treatment of invasive fungal infections.

@nl

prefLabel

New and investigational triazole agents for the treatment of invasive fungal infections.

@en

New and investigational triazole agents for the treatment of invasive fungal infections.

@nl

P1433

Q37364295-F33BB5E9-71BA-448D-8C64-EE4848C27433

P1476

Q37364295-A35D5618-4AF8-4039-8B66-828317C08BF4

P2093

Q37364295-7EDA534C-C4C2-416C-B6DF-D649B5AC1A02

Q37364295-AA8F8C4C-67F0-40A4-B9BF-9B8FC78EA70A

Q37364295-BDFAEE21-C986-435D-821F-F71E23AAD1E3

P2860

Q37364295-07119FBB-F530-4A04-B278-05ACEC20900F

Q37364295-0998C555-A54F-4BEB-9618-EC3E5701ED54

Q37364295-0AD36254-EAA0-4AC2-857A-0C5AE2D04DC7

Q37364295-0F3136AC-8BB1-49FA-8E77-1BC76741141D

Q37364295-120E998E-47AC-46B6-921E-CF9FE1FC0716

Q37364295-12715007-4468-400A-AEAF-2C1B8CDF3984

Q37364295-147C3FE9-5E60-4F5B-B8BA-C811F87B0322

Q37364295-187EF981-5793-4B32-8B93-F408111CA841

Q37364295-1E637FA2-4E25-45B2-B74A-21440BC6034C

Q37364295-263DE627-E38D-464E-B5C0-5E227A6F5CBD

P304

Q37364295-8BC0789E-D8A6-43B4-9DCE-88AF999C1B61

P31

Q37364295-CF947E56-E29C-4EE6-AE91-DF197150F3E6

P356

Q37364295-20CD5E57-7358-432F-AEAC-3517CEE8CFAC

P433

Q37364295-22041CBC-BE6D-41CD-9698-FF681810CF56

P478

Q37364295-0C521C33-AAE0-4F00-9CDA-C2BEE3FDF114

P577

Q37364295-037EF1E8-BC8D-45BD-A257-AD5AC8AE779B

P698

Q37364295-664B46D2-86D7-44F5-AF3C-0B7841E8D7B5

P356

JOC.2008.20.6.661

P1433

Journal of Chemotherapy

P1476

New and investigational triazole agents for the treatment of invasive fungal infections.

@en

P2093

De Sarro A

http://www.w3.org/2001/XMLSchema#string

Fera MT

http://www.w3.org/2001/XMLSchema#string

La Camera E

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B

In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi

In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi

In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.

P304

661-671

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1179/JOC.2008.20.6.661

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19129062

http://www.w3.org/2001/XMLSchema#string